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ABSTRACT
Objectives: To explore the expression patterns of
Eag1 (ether á go-go 1) and HIF-1α (hypoxia-inducible
factor 1α) in a cohort of patients with breast cancer.
Setting: Department of general surgery in an upper
first-class hospital in Xi’an, China.
Participants: A total of 112 female Han Chinese
patients with a diagnosis of invasive ductal carcinoma
were included. Patients with main internal diseases,
such as cardiovascular, endocrine, gastroenterological,
haematological, infectious diseases, etc, were
excluded.
Primary and secondary outcome measures:
Expression profiles of Eag1 and HIF-1α.
Results: Eag1 and HIF-1α were overexpressed in the
tumour tissues compared with the pair-matched
control tissues, p=0.002 and <0.001, respectively. The
expression of Eag1 and HIF-1α was negatively
correlated with tumour size, p=0.032 and p=0.025,
respectively, and lymph node status (p=0.040,
p=0.032, respectively). The coexpression of Eag1 and
HIF-1α was correlated with tumour size (p=0.012),
lymph node status (p=0.027) and tumour stage
(p=0.036). HIF-1α has a strong correlation with hEag1
expression (κ=0.731, p<0.001).
Conclusions: HIF-1α expression has a strong
correlation with hEag1 expression. We are the first to
attempt to explore the correlation at the population
level.
INTRODUCTION
Breast cancer is the leading cause of cancer-
related deaths in women, accounting for
37.4% of female deaths worldwide.1 It is pre-
dicted that breast cancer incidence will
increase to ∼85/100 000 women in China by
2021.2 Breast cancer is easier to cure in its
early stages, and early diagnosis provides vital
information for doctors to make proper and
effective plans for each individual. There are
existing biomarkers for breast cancer, such as
BRCA1 and BRCA2, but their utility can be
improved through combination with other
new biomarkers.3 Voltage-gated potassium
channels have been shown to play a role in
breast cancer, and among them, Kv1.3 has
been identified as a potential diagnostic
marker and therapeutic target for breast
cancer.4
Ether á go-go 1 (Eag1, Kv10.1, KCNH1) is
a member of the potassium channel family.
Eag1 is the first voltage-gated potassium
channel that has been shown to mediate
cancer progression.5 The expression of Eag1
is restricted to the brain of healthy adults,
but it is also expressed in many tumour cells
and tissues, such as breast cancer6 and cer-
vical cancer.7 Moreover, Eag1 is important
for tumour cell proliferation.5 The inhibition
of Eag1 expression using antisense oligonu-
cleotides or siRNA, or pharmacological
inhibition with imipramine, astemizole or
quinidine can reduce cell proliferation in
cancer cell lines.6 8–10 The blockade of Eag1
by a specific monoclonal antibody or astemi-
zole also inhibits tumour growth in vivo.11 12
In acute myeloid leukaemia (AML), channel
expression was strongly correlated with
increasing age, higher relapse rates and sig-
nificantly shorter overall survival in the
Caucasian population.13 In ovarian cancer,
Strengths and limitations of this study
▪ The study found positive correlation between the
expression of hypoxia-inducible factor 1α
(HIF-1α) and ether á go-go 1 (Eag1), and nega-
tive correlation with several clinical parameters,
including tumour size and node status.
▪ The study provided highly relevant clinical
support for previously published mechanistic
studies and might be useful in the development
of clinical and therapeutic biomarkers.
▪ A computerised pO2 histography system could
reveal the change of the oxygen level as the
tumour progresses, which might explain the
negative correlation between Eag1 and/or HIF-1α
and clinical parameters.
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the expression of Eag1 is associated with poor survival in
the Caucasian population.14 These previous epidemio-
logical investigations are in accordance with researches
at molecular and cellular levels which indicate that Eag1
favours oncogenesis and tumour progression.
The mechanism of Eag1’s role in oncogenesis and
cancer progression is not known yet. Interference with
the cellular oxygen homoeostasis system was proposed as
the potential mechanism for the oncogenic role of
Eag1.12 This hypothesis was based on evidences col-
lected at the cellular level. In NIH3T3 and Chinese
hamster ovary cells, hypoxia-inducible factor 1α
(HIF-1α) levels and vascular endothelial growth factor
(VEGF) secretion were elevated by Eag1 expression.12
When these Eag1-expressing cells were implanted into
severe combined immune deficient (SCID) mice,
tumours were induced.12 Eag1-expressing tumours
showed increased angiogenesis compared with the
Eag1-negative mock cells.12 Eag1 was proposed to inter-
fere with hypoxia homeostasis by increasing basal HIF-1
activity and lowering the threshold of HIF-1α activation
by hypoxia. This results in VEGF secretion and thereby
increased tumour vascularisation. The correlation
between Eag1 and HIF-1α has been proved at the cellu-
lar level.12 It would be much more supportive if this
hypothesis could be proved at the population level.
As an anticancer target, Eag1 has the advantages of
easy accessibility, a single molecule real-time ion channel
monitor15 and a reduced likelihood of increasing multi-
drug resistance as a potential regulator in tumour angio-
genesis under hypoxia.16 Additionally, the channel has
an extraordinarily clean background.15 Eag1 could be
one of the factors which could help in making proper
clinical decisions for each individual patient.
HIF-1 is the master regulator of oxygen homeostasis
and is composed of HIF-1α and HIF-1β subunits.17
HIF-1α is degraded in non-hypoxic cells, whereas HIF-1β
is constitutively expressed.17 HIF-1 activates the transcrip-
tion of genes, for example, VEGF, that are important
for tumour angiogenesis.18 In bladder cancer, the
expression of HIF-1α was closely related to tumour
angiogenesis and tumour stage.19 In breast cancer,
there are controversial reports. In human breast cancer
cell lines, there was an inverse correlation between
HIF-1α induction and clonogenic survival under
hypoxia.20 But HIF-1α was correlated with high metasta-
sis risk and poor overall survival in the Caucasian popu-
lation.21 The complicated mechanisms of the HIF-1α
pathway need more evidence to elucidate the signal
transduction in hypoxia-induced angiogenesis in cancer
progression.
In the present study, we aimed to explore the expres-
sion patterns of Eag1 and HIF-1α and the clinical signifi-
cance of their expression with respect to tumour size,
lymph node status, tumour stage, patient age at surgery
and body mass index (BMI) at surgery. This is the first
study to examine the correlation between Eag1 and
HIF-1α at the population level.
MATERIALS AND METHODS
Patients and tissues
The study enrolled 112 patients from the department of
surgery, Xijing Hospital, Xi’an, China, from July to
December 2009. The equation
M=m/(p0q1+p1q0), m={Zα/2+Zβ (p(1−p))0.5}2/(p−1/2)2
was used to assess the size of the sample (M). As there is
no previous data on the expression of Eag1 in normal
breast tissues or breast cancer tissues in the Chinese Han
population, we carried out a pilot study to get data on the
expression of Eag1 in breast cancer tissues and adjacent
normal tissues. Eag1 was positively expressed in 93.8%
(30/32) of breast cancer tissues and 56.3% (18/32) of
adjacent normal tissues. So we take α=0.05, β=0.10. The
sample size should be 22. In practice, 112 samples were
analysed for the accuracy of the study. Patients were diag-
nosed with invasive ductal carcinoma (IDC) according to
the WHO classification criteria.22 Breast cancer tissues
from patients undergoing surgery were collected as case;
adjacent normal tissues excised from more than 0.5 cm
outside of the tumour served as control. Formalin-fixed,
paraffin-embedded surgical specimens were examined.
Lymph node status was determined through biopsy.
Tumour stage was determined according to the American
Joint Committee on Cancer (AJCC) Tumour size, Lymph
Nodes affected, Metastases (TNM) criteria.23
This study was approved by the ethics committee of
Xijing Hospital and was conducted in accordance with
the principles of the Helsinki Declaration II. Informed
consent was obtained from all participants.
Immunohistochemical staining
Immunohistochemical analysis was performed as
reported by Hemmerlein et al.7 Serial 4 µm sections were
prepared, and one was stained with H&E. Slides were
deparaffinised with xylene and rehydrated in graded solu-
tions of ethanol and distilled water. Optimal staining con-
ditions and antibody dilutions were determined using
formalin-fixed and paraffin-embedded tissue samples
from human cerebral cortex for Eag1. Samples from a
specimen of colon adenocarcinoma with strong expres-
sion of HIF-1α were used to determine the optimal stain-
ing conditions and antibody dilutions for HIF-1α.
Negative controls were performed using non-immune
serum or phosphate-buffered saline (PBS) instead of the
primary antibody. The antibodies against Eag1 and
HIF-1α showed good specificities. Antigen retrieval was
performed in a microwave oven in 10 mM citrate buffer
(pH 6.0) at 700 W for 15 min. Tissue sections were prein-
cubated with normal goat serum (Zhongshanjinqiao,
Beijing, China) at a 1:100 dilution in 3% bovine serum
albumin/PBS. Slides were incubated overnight in a
humidified chamber at 4°C with anti-Eag1 rabbit anti-
serum (Abcam, ab86204) at a 1:1200 dilution or
anti-HIF-1α mouse antiserum (Abcam, ab80544) at a 1:50
dilution, followed by incubation with the EnVision
Peroxidase System and DAB (Zhongshanjinqiao, Beijing,
China). The same protocol was used for oestrogen
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receptor α (ERα) with anti-ERα antiserum (Abcam,
ab37438) at a 1:50 dilution and for human epidermal
growth factor receptor 2 (HER2) with anti-HER2 anti-
serum (Abcam, ab16901) at a 1:100 dilution.
Two operators independently evaluated antigen expres-
sion, scoring it either as ‘negative’ (0) or ‘positive’ (1), as
appropriate. When the two operators agreed on the same
diagnosis, the conclusion was accepted; when they gave dif-
ferent diagnoses, a discussion was carried out to reach an
agreement. Slides with less than 10% positive staining cells
were considered to be negative, and those with at least
10% positive staining cells were considered positive.22
Statistical analyses
Quantitative variables were categorised into groups, for
example, T1, T2 and T3 for tumour size; N0, N1, N2
and N3 for lymph node status; M0, M1 and M2 for
tumour metastasis.
A rank-sum test was used to compare the differential
expression of Eag1 and HIF-1α between breast cancer
tissues and matched adjacent normal tissues.
Spearman’s rank correlation was used to evaluate the
correlation between the expression of Eag1 and HIF-1α
and clinical parameters in cancer tissues. κ Coefficient
was used to evaluate the agreement between HIF-1α and
Eag1 expression in cancer tissues, and the correlation
between ERα and HER2 status with Eag1 and HIF-1α.
Two-sided significance tests were used throughout,
and p≤0.05 was considered statistically significant. The
statistical analyses were performed using SPSS V.19.0 for
Windows (SPSS Inc, Chicago, Illinois, USA).
RESULTS
We examined the expression of Eag1 and HIF-1α in 112
breast cancer tissue samples and adjacent normal tissue
samples. The age of the patients ranged from 22 to
84 years (median 56). All 112 patients were women.
There were 112 breast cancer tissue samples and 112
adjacent normal samples. Twelve patients had stage I
breast cancer, 77 patients had stage II breast cancer and
23 were stage III. Patients with stage III breast cancer
had a median age of 49.5, which was lower than the
median age of patients with stages I and II breast cancer.
Patients with lower stages had higher levels of Eag1 and
HIF-1α expression (table 3). Among these patients, 45
had tumours located in the left breast, and 67 were in
the right breast (table 1).
Representative images of immunohistochemical ana-
lyses for Eag1 and HIF-1α are shown in figure 1.
Consistent with the expected intracellular localisation,
Eag1 was detected at the cell membrane and in the cyto-
plasm, whereas HIF-1α expression was observed inside
the nucleus and in the cytoplasm.
Overexpression of Eag1 and HIF-1α in breast cancer tissue
Eag1 was detected in 85.7% (96/112) of the breast
cancer tissue samples from the 112 patients, but it was
expressed in only 64.3% (72/112) of the adjacent
normal tissues. Eag1 was overexpressed in breast cancer
tissue compared with matched normal tissue (p=0.002;
table 2).
HIF-1α expression was found in 79.5% (89/112) of
breast cancer cases but in 39.3% (44/112) of normal
tissue surrounding the tumours (table 2). HIF-1α was
overexpressed in breast cancer tissue compared with
matched normal tissue (p<0.001; table 2).
Correlation between expression of Eag1 and HIF-1α and
clinical parameters of tumours
Elevated Eag1 expression was significantly associated
with reduced tumour size (p=0.032) and low lymph
node status (p=0.040; table 3). No significant correlation
was observed between Eag1 expression and age
(p=0.257), BMI (p=0.235) or tumour stage (p=0.083;
table 3).
HIF-1α expression was inversely correlated with
tumour size (r=−0.212, p=0.025) and lymph node status
(r=−0.207, p=0.032). No significant correlation was
observed between HIF-1α expression and age (p=0.626),
BMI (p=0.063) or tumour stage (p=0.056; table 3).
In adjacent normal tissues, the coexpression of Eag1
and HIF-1α was correlated with lymph node status
(p=0.016). No other significant correlation was found
(see online supplementary table S1).
Eag1 expression is correlated with HIF-1α expression in
breast cancer tissue
The most important finding comes when Eag1 and
HIF-1α are considered together. As shown in table 4,
there is a correlation between the expression of Eag1
and HIF-1α (p<0.001) in breast cancer tissue samples. κ
Coefficient shows the agreement between HIF-1α and
Eag1 expression in cancer tissues. This correlation is
consistent with the studies at the cellular level. Further
more, the coexpression of Eag1 and HIF-1α was corre-
lated with BMI before surgery (p=0.032), tumour size
(p=0.012), lymph node status (p=0.027) and tumour
stage (p=0.036; table 3).
Table 1 Clinical features of the 112 patients with breast
cancer
Clinical parameter N (%)
Mean age (range) 56.1 (22–84)
Tumour size (range) 3.5 (1.0–9.7)
Tumour in left breast 45 (40.2)
Tumour stages
I 12 (10.7)
II 77 (68.8)
III 23 (20.5)
Lymph node status
Positive 81 (72.3)
Negative 31 (27.7)
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Correlation analysis of ERα and HER2 status with Eag1
and HIF-1α
The expression of ERα and HER2 was measured in each
patient. There was no significant correlation between
either of the hormone receptors and Eag1 or HIF-1α.
Tables showing the results are available online as data
supplement (see online supplementary tables S2–S5).
DISCUSSION
The expression of Eag1 and HIF-1α was studied in a
cohort of patients with breast cancer from a Han
Chinese population. The study found positive correl-
ation between the expression of HIF-1α and Eag1, and
negative correlation with several clinical parameters,
including tumour size and node status.
Hemmerlein et al7 reported that Eag1 was overex-
pressed in breast cancer (85% or 82% using either a
whole monoclonal antibody against EAG or a recombin-
ant alkaline phosphatase/single chain antibody fusion,
respectively). Abnormal Eag1 expression has also been
reported in prostate cancer,7 AML13 and ovarian
cancer.14 The overexpression of Eag1 was validated in
this study, and Eag1 was expressed in 85.7% of breast
cancer tissues versus 64.3% of the adjacent normal
tissues. For HIF-1α, the ratio was 83.9% in breast cancer
tissues versus 38.4% in the normal counterparts.
Eag1 expression is positively correlated with some clin-
ical parameters, such as tumour size in head and neck
cancer24 and lymph node metastases in colorectal
cancer.25 Eag1 expression was associated with clinical
parameters in different categories of cancer, including
Figure 1 Representative images of breast cancer tissue staining. Ether á go-go 1 (Eag1) was not detected in adjacent normal
breast tissues (A) but found at the cell membrane and in the cytoplasm in breast cancer tissues (B). The adjacent normal breast
tissues show hypoxia-inducible factor 1α (HIF-1α)-negative staining (C), while HIF-1α expression was found inside the nucleus in
breast cancer tissues (D). Eag1 was found in the cytoplasm and the cell membrane (brown, white arrowhead) while not in the
nucleus (blue, black arrowhead; E). HIF-1α was found inside the nucleus (brown, black arrowhead) and the cytoplasm (brown,
white arrowhead; F). (H&E counterstain). Original magnifications: ×400 (A–D); ×1000(E and F).
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epithelial origin cancers and non-epithelial origin ones.
AML is a haematopoietic, non-epithelial origin cancer.
In the 118 patients with AML, a subtype-dependent
expression of hEag1 was found. In the most common
subtypes of AML, 50% of the cases were Eag1 positive.13
Furthermore, this correlated with increasing age, higher
relapse rates and significantly shorter overall survival.13
Eag1 has been correlated with poorer prognosis in
AML,13 ovarian,14 colorectal25 and oesophageal
cancer.26 But there is no evidence for the effect of Eag1
expression in breast cancer. We demonstrated that Eag1
was inversely correlated with tumour size and lymph
node status in the 112 patients with IDC examined.
For Eag1, our research is the first attempt in breast
cancer study. But this negative correlation is different
from a previous study in which Eag1 expression posi-
tively correlates with clinical parameters. Yet, there is a
possibility that the effect of Eag1 expression is cancer-
type dependent and population dependent. Eag1
channel undergoes glycosylation and other post-
translational modifications27 which are not detected by
immunohistochemistry. Eag1 may play a role in the early
stages of breast cancer and then degrade. Eag1 was
proposed to interfere with hypoxia homeostasis,12 which
occurs in the early stages of tumour development.28 The
exploration of Eag1 function was performed in SCID
mice by injection of cells into the subcutaneous space.5
This strategy does not replicate the tumoural microenvir-
onment in which cancer cells normally develop. The
microenvironment is important for Eag1 to interfere
with hypoxia homeostasis. This could be an explanation
for the negative correlation between Eag1 expression
and breast cancer tumour stage.
We demonstrated that HIF-1α expression is inversely
correlated with tumour size and lymph node status. In
other types of cancer, HIF-1α was a marker for unfavour-
able prognosis, such as in early-stage invasive cervical
cancer.29 It was associated with increased lymph node
metastasis and worse survival in oesophageal squamous-
cell carcinoma30 and oropharyngeal cancer.31 But in
non-small-cell lung carcinomas,32 patients with
HIF-positive carcinomas had significantly longer median
survival times than patients with HIF-negative carcin-
omas. Conflicting reports20 21 on HIF-1α and breast
cancer may implicate that HIF-1 has more than one way
to affect tumour progression.
It is reported that HIF-1α is expressed in the early
stages of breast cancer33 which has an important role in
cancer progression.34 Increase of HIF-1α activity by Eag1
results in VEGF secretion and thereby increased tumour
vascularisation.12 There is a report about VEGF’s nega-
tive correlation with breast cancer tumour grade.34
Activation of angiogenic phenotype also occurs early in
tumour development and is the rate-limiting step for
Table 2 The expression of human ether á go-go 1
(hEag1) and hypoxia-inducible factor 1α (HIF-1α) in breast
cancer tissues and adjacent normal tissues†
Protein Expression
Breast
cancer
tissue
Adjacent
normal
tissue
p
Value
Eag1 + 87 72 0.002*
− 25 40
HIF-1α + 89 44 <0.001
− 23 68
*p<0.05.
†There were 112 breast cancer tissues and 112 adjacent normal
tissues. Eag1 had a different distribution between (87/112) cancer
tissues and (72/112) adjacent normal tissues (p=0.002). HIF-1α
was detected in 89 cancer tissues and 44 adjacent normal tissues
(p<0.001). A rank-sum test was used to compare the differential
expression of Eag1 and HIF-1α between breast cancer tissues
and matched adjacent normal tissues.
Table 3 Correlation between expression of Eag1 and HIF-1α and clinical parameters of tumours†
Eag1 HIF-1α Coexpression
Variables r p Value r p Value r p Value
Age at operation −0.108 0.257 −0.047 0.626 0.077 0.417
BMI at operation 0.209 0.235 0.356 0.063 −0.406 0.032*
Tumour size −0.203 0.032* −0.212 0.025* 0.236 0.012*
Lymph node status −0.199 0.040* −0.207 0.032* 0.212 0.027*
Tumour stage −0.164 0.083 −0.181 0.056 0.199 0.036*
*p<0.05, r: correlation coefficient.
†Spearman’s rank correlation coefficient was used to evaluate the correlation between the expression of Eag1 and HIF-1α and clinical
parameters in cancer tissues. A rank-sum test was used to calculate the differences in tumour size, lymph node status and tumour stage of
patients between the Eag1+ HIF-1α+ group and other cancer tissues.
BMI, body mass index; Eag1, ether á go-go 1; HIF-1α, hypoxia-inducible factor 1α.
Table 4 Correlation/agreement between
hypoxia-inducible factor 1α (HIF-1α) and ether á go-go 1
(Eag1) expression in breast cancer tissue†
HIF-1α (+) HIF-1α (−) κ p Value
Eag1 (+) 86 6 0.731 <0.001
Eag1 (−) 3 16
†Spearman’s correlation was used to calculate the correlation
between HIF-1α and Eag1 in cancer tissues. κ Coefficient was
used to evaluate the agreement between HIF-1α and Eag1
expression in cancer tissues.
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tumour progression.35 36 In this situation, if we get the
biopsy later, Eag1 and HIF-1α will not be detected.37
The coexpression of Eag1 and HIF-1α was correlated
with BMI before surgery, tumour size, lymph node status
and tumour stage. This result implies that an interaction
between Eag1 and HIF-1α might play a role in breast
cancer.
More importantly, the expression of Eag1 correlates
with the expression of HIF-1α. The correlation between
Eag1 and HIF-1α was observed under hypoxia.12
Hypoxia occurs in the early stages of tumour develop-
ment.20 The disease-free and overall 6-year survival rates
were reported to have increased twofold in patients with
cervical cancer with well-oxygenated tumours.14 Similar
results occurred in head and neck cancer24 and soft
tissue sarcomas.38 Eag1 was expressed in all three well-
oxygenated tumour types. Shorter overall and shorter
recurrence-free survival was observed for patients with
hypoxic tumours in which Eag1 was not detected.33
As shown in figure 1, Eag1 localises at the cell mem-
brane and in the cytoplasm, while HIF-1α localises in
the cytoplasm and inside the nucleus in breast cancer
tissues. Consistent with the existing reports on Eag1 and
HIF-1α,39–42 the present study showed that there are sub-
cellular location overlaps between Eag1 and HIF-1α, sug-
gesting the two proteins could interact with each other
in the cytoplasm. Indeed costaining could provide direct
cellular evidence that Eag1 and HIF-1α are coexpressed
in breast cancer tissues; however, the localisations of
Eag1 and HIF-1α in the cytoplasm make it difficult to
costain these two proteins in the same area of cancerous
tissue.
CONCLUSION
In the present study, we validated that Eag1 and HIF-1α
were coexpressed in most breast cancer samples
(91.1%). The correlation between the expression of
Eag1 and HIF-1α in breast cancer tissues is in accord
with the cellular research.12 The study provides highly
relevant epidemiological support for previously pub-
lished mechanistic studies on Eag1 and might be useful
in the development of clinical and therapeutic
biomarkers.
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